

**REMARKS**

Pursuant to 37 C.F.R. § 1.98 copies of the U.S. patent documents (patents, application publications, and applications), if any, are not being submitted herewith. Of course, should any of the documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

Applicants note that Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

Applicants note that this disclosure statement is being filed after first action on the merits, but prior to issuance of an office action closing prosecution. Therefore, a fee including the amount of \$180.00 is submitted herewith. However, if the fee is deficient and/or if any additional fee is required for consideration of this disclosure statement, including any fee under 37 C.F.R. 1.17(p), Applicants hereby authorize that any required fee be charged to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicants respectfully request that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: May 4, 2009

/Wesley A. Nicolas, Reg. No. 56,129/  
Wesley A. Nicolas, Reg. No. 56,129  
Novo Nordisk, Inc.  
Customer Number 23650  
(609) 987-5800